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Abstract
Genetic analysis is currently offering glimpses into molecular mechanisms underlying such 
neuropsychiatric disorders as schizophrenia, bipolar disorder and autism. After years of 
frustration, success in identifying disease-associated DNA sequence variation has followed from 
new genomic technologies, new genome data resources, and global collaborations that could 
achieve the scale necessary to find the genes underlying highly polygenic disorders. Here we 
describe early results from genome-scale studies of large numbers of subjects and the emerging 
significance of these results for neurobiology.
Schizophrenia, bipolar disorder and autism are neuropsychiatric syndromes that produce 
severe symptoms and significant, often life-long, disability. Unfortunately, knowledge of 
disease mechanisms has been scant, and existing treatments benefit only a subset of the 
disease symptoms and even then only incompletely. For example, antipsychotic drugs, all of 
which act by antagonizing D2 dopamine receptors, are partly effective for alleviating 
hallucinations, delusions and other psychotic symptoms that occur in schizophrenia, bipolar 
disorder, severe forms of depression and neurodegenerative disorders. However, there is no 
effective pharmacologic treatment for the disabling deficit symptoms of schizophrenia (such 
as blunted affect, decreased motivation and impoverished thought and speech) or for 
cognitive impairments (such as deficits in attention, working memory, verbal fluency, 
declarative memory and social cognition). All widely used psychiatric medications are based 
on prototype drugs that were serendipitously discovered in the period between 1949 
(lithium) and 1957 (the antidepressants and benzodiazepines); no significant new class of 
drugs has been introduced to the clinic since then. Contributing to this lull in discovering 
new therapeutic agents is the lack of insight into the molecular mechanisms of these 
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disorders. Across all of medicine, molecular insight has proven to be the most important 
information needed to identify and validate drug targets and to discover biomarkers. The 
advent of genomic technologies of the early twenty-first century has allowed, for the first 
time, detailed examination of the genetic basis of many non-Mendelian diseases. Here we 
review advances in the genetics of psychiatric disorders, what neuroscientists can take away 
from these studies, and how best to apply the resulting information toward investigating the 
neurobiology of these complex and heterogeneous disorders.
Psychiatric genetics before 2009
Unlike the situation for some neurodegenerative disorders such as Alzheimer's disease, 
brains of patients with neuropsychiatric disorders such as schizophrenia, bipolar disorder 
and autism have not yielded predominant biochemical abnormalities (such as plaques) that 
could be exploited scientifically, nor have rare Mendelian forms of these diseases been 
identified except for rare syndromal forms of autism. Nonetheless, these neuropsychiatric 
disorders run in families, and twin and adoption studies show them to be highly influenced 
by genes. On the basis of these observations, attempts to identify disease-associated DNA 
variation began more than two decades ago. However, the non-Mendelian patterns of 
segregation in families, and the non-Mendelian ratios seen when comparing concordance for 
disease between monozygotic twin pairs (who share 100% of their DNA sequences) and 
dizygotic twin pairs (who share, on average, 50% of their DNA sequences), portended a 
degree of polygenicity that stymied early attempts to use genetics to discover molecular 
mechanisms of pathogenesis.
Twin studies indicate that schizophrenia, bipolar disorder, autism and attention deficit 
hyperactivity disorder (ADHD) are among the most heritable of any common, genetically 
complex medical disorders. (Heritabilities for these four disorders fall in the range of 0.65–
0.80; ref. 3.) In twin studies, the rate of concordance for a phenotype is compared between 
monozygotic and dizygotic twin pairs, permitting an estimate of the contribution of inherited 
and non-inherited factors to phenotypic variance. More recently, specific components of 
heritability4 have also been estimated on the basis of common DNA sequence variants 
across the genome shared by unrelated individuals. Significant lower bounds have been set 
for the heritabilities of schizophrenia, bipolar disorder, autism, ADHD and major depressive 
disorders5.
A problem in older genetic studies was the widely held hypothesis that named psychiatric 
disorders each represented natural, independent categories that might be expected to breed 
true. In fact schizophrenia and bipolar disorder co-occur in the same families at rates far 
greater than chance expectation6. On the basis of prevailing models, such families were 
often considered to be anomalous and were often excluded from genetic studies. It is now 
apparent, however, that psychiatric disorders, as currently defined, share a high percentage 
of risk-associated genes with one another5,7, a connection that at least partly explains the 
high frequencies of shared symptoms across diagnoses, of patients being diagnosed with 
multiple disorders, and of patients receiving different diagnoses at different times in their 
lifespans.
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There is today wide recognition of the scientific limitations of psychiatric disorder 
definitions within current standard nosologies, the Diagnostic and Statistical Manual of 
Mental Disorders, 5th Edition (DSM-5)8 and the International Classification of Diseases, 
10th Edition9. These manuals erroneously represent psychiatric disorders as categories 
qualitatively distinct from normalcy and from one another. Recent data from genetics, 
cognitive neuroscience, imaging and clinical observation argue that psychiatric disorders are 
better understood as heterogeneous spectra that deviate from health quantitatively but not 
qualitatively, in analogy to hypertension or dyslipidemias10. Moreover, lacking objective 
biomarkers, the DSM system defines disorders in terms of fairly arbitrary constellations of 
symptoms. As a result many distinctions between disorders are not empirically supported, 
and unsurprisingly, many symptomatic individuals fall outside specific diagnostic categories. 
Such limitations in phenotyping would seem inconsistent with the possibility that DSM-
defined psychiatric disorders could exhibit high heritabilities or aid in successful gene-
discovery efforts. In fact, for schizophrenia, bipolar disorder and autism, the symptoms, 
typical ages of onset and courses of illness have been well documented apart from DSM 
diagnoses. Nonetheless, the limitations of the DSM system have likely contributed to the 
`noisiness' of patient data sets and thus, along with the complexity of the genetic 
architecture, have contributed to the need for larger population samples than are required for 
genetic analysis of many polygenic diseases outside of psychiatry. Ultimately genetics will 
contribute, along with other measures, to significant revisions in psychiatric diagnosis. 
However, the pleiotropy of many risk-associated genes suggest that genetics alone will not 
prove sufficient to make diagnoses for common psychiatric disorders.
With the advent of genetic linkage methods (Box 1), many scientists in the 1980s and 1990s 
took up the challenge of trying to identify genomic segments that co-segregated with 
neuropsychiatric disorders in families with multiple affected individuals. The hypothesis 
underlying linkage analyses is that family members who share a disease phenotype do so as 
a result of one or a few shared, highly penetrant risk alleles. While linkage analyses 
successfully identified penetrant mutations associated with rare familial forms of 
Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis, it failed to 
discover widely replicated genetic association in psychiatric disorders.
Why did linkage analysis fail for psychiatric disorders when it was successful for so many 
diseases with simple Mendelian patterns of inheritance, including familial Alzheimer's 
disease? The genetic architecture of psychiatric disorders may be more complex, such that 
even when a family carries a risk variant of large effect, it tends to be far less penetrant than 
loci that `cause' familial Alzheimer's disease or cystic fibrosis. Moreover, even in the 
situation in which a family carries a rare variant of large effect, other superficially similar 
families are likely to carry different rare variants. Thus linkage evidence will not accumulate 
for any specific locus. Second, individuals affected by psychiatric disorders may carry many 
alleles that influence their risk. Such risk variants may aggregate in individuals and families 
by chance such that even in the same family affected individuals may have both shared and 
unshared risk alleles. Evidence from the study of common variants (see Fig. 1) supports this 
model. Genetic risk arises from many different genes, both within individuals and across 
families, and from rare and common variants at the same time. When disorders arise in 
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different families from the effects of alleles in many different genes – the definition of a 
polygenic trait – the assumptions underlying linkage analysis are violated.
Another unsuccessful effort to identify disease-associated genes in psychiatric disorders 
involved biological candidate-gene studies (Box 2). These studies, which gained much 
attention during the 1990s and into the 2000s, attempted to use knowledge of biology to 
nominate candidate genetic variants for association studies. Candidate-gene studies ask 
whether a particular allele of a gene of interest is statistically associated with a disease (or 
other phenotype of interest) by comparing the genotypes of ill subjects to those of healthy 
control subjects. The underlying assumption was that the molecular biology of mental 
disorders (or of interindividual differences in cognitive capacities or emotion processing) 
was well enough understood to make it possible to nominate candidate genes with 
substantial prior probabilities of association. In schizophrenia, more than 1,400 candidate-
gene studies were published, of which half focused on the same 18 genes (http://szgene.org). 
Owing perhaps to an inadequate understanding of multiple hypothesis testing, candidate-
gene studies were often reported as having positive results whenever any tested association 
reached a nominal significance level (such as p = 0.05). In a field in which thousands of such 
hypotheses are tested each year, it is expected that—even in the absence of any true 
underlying genetic relationships—hundreds of such analyses will arrive by chance at p-
values that reach this modest threshold. For example, while a PubMed search can find large 
literatures on DISC1, NRG1 and other candidate genes in schizophrenia, the actual results 
appear random and show little or no consensus on the genetic variants reported as positive or 
on the directionality of their putative effects. Moreover, today's genome-wide studies, having 
examined these same alleles in large, well-powered cohorts (see below), do not find even 
modest evidence for association at most of these candidate loci.
Neuropsychiatric genetics since 2009: accelerating progress
Unbiased analyses of the entire genome, pursued in large cohorts of affected and unaffected 
individuals, have recently demonstrated associations of many specific genomic loci with 
schizophrenia, bipolar disorder and autism. Many results have already been replicated in 
other patient populations and are statistically conclusive. Several factors have made this 
success possible.
The first is a new understanding of human genome sequence, structure and variation. Over 
the decade since the Human Genome Project was completed, extensive study has revealed 
how the sequence and structure of genomes vary from person to person12–15. Although it 
may be unsurprising that healthy human being are not each an isogenic `wild-type' organism 
in which functional mutations clearly stand out, the degree of variation among individuals is 
remarkable. A key insight is that functional variation abounds in every human genome: each 
human genome contains thousands of alleles that alter the protein sequence or expression of 
genes. This large pool of functional variation across human populations provides the grist 
for polygenic inheritance. On a practical level, databases of genome sequences and sequence 
variants support the design of technologies for genome-wide SNP genotyping (Box 3), 
analysis of copy number variations (CNVs, Box 4), and exome sequencing (Box 5).
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A second important factor has been technological innovation in the molecular tools used to 
analyze genome sequence variation. A microarray-based analysis can type the common 
single-nucleotide polymorphisms (SNPs) (Box 3) and identify the large CNVs (Box 4) that 
are present in an individual's genome for about $100 today. The design of these microarrays 
is informed by data from the 1000 Genomes Project, making results extensible to untyped 
SNPs through the use of well-accepted statistical techniques that exploit the tendency of 
genomically nearby SNP alleles to segregate together as a haplotype16. The cost of 
sequencing has fallen dramatically, by 5–7 orders of magnitude since the Human Genome 
Project. Today the protein-coding parts of the genome (the `exome', Box 5) are routinely 
sequenced for under $1,000. With recently announced innovations in sequencing technology, 
whole genomes will soon be sequenced for about $1,000. Such innovations make it both 
technically possible and affordable to conduct studies of rare sequence variation in 
thousands of individuals17. Although genome sequencing platforms are costly to set up and 
maintain, there is enough capacity in many research communities for individual investigators 
to gain access at low cost.
The third key factor has been a scientific understanding of the scale required to be 
successful. Scale is important for two reasons. First, consistent with the complexity of the 
molecular, cellular and circuit-based substrates of all cognitive processes and behavior, the 
heritability of psychiatric disorders appears to be distributed across many hundreds of loci, 
with each individual locus explaining only a small fraction of the overall heritability of the 
phenotype in populations. Second, an unbiased genome-wide search comes with a great 
burden of multiple hypothesis testing: an association is meaningful only if it is very unlikely 
to have arisen by chance. High levels of evidence are therefore necessary to definitively 
implicate any individual genetic locus. (GWAS routinely use a significance threshold of 5 × 
10−8.) In common-variant association studies (Box 3), clear drivers of recent success are 
meta-analyses by large consortia of data from across the field. The current analysis of 
schizophrenia risk by the Psychiatric Genomics Consortium encompasses data from 52 
study cohorts and from 82,000 individual human genomes. The size of such studies allows 
them to implicate individual loci with genome-wide significance and insulates them from 
many potential artifacts involving genotyping error and population substructure. Rare-
variant association studies based on whole-exome or whole-genome sequencing are also 
beginning to reach substantial scale. In schizophrenia, the largest such studies to date 
included a case-control cohort of 5,000 individuals and a separate study of 600 father-
mother-proband trios17,18, and studies of autism trios by exome sequencing have covered 
about 1,000 trios collectively19–22. Increased scale will almost certainly be enabled by recent 
and future innovations in sequencing technology.
Interpreting emerging genetic results: common variants
Genetic discoveries with strong statistical support are emerging abundantly today from 
common-variant association studies (CVAS), which are most often called genome-wide 
association studies (GWAS). As described in Box 3, the convincing levels of evidence 
emerging from these studies reflect the ability to evaluate common alleles in thousands of 
subjects with diverse genetic backgrounds. Large-scale meta-analyses by international 
consortia have confidently identified 20 loci with risk of Alzheimer's disease (in a study of 
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72,000 genomes)23, 10 or more loci affecting bipolar disorder (15,000 genomes) and 100 or 
more loci affecting schizophrenia (82,000 genomes). These results reflect high levels of 
statistical significance; many are also supported by replication analyses in multiple 
cohorts24,25. Moreover, the strong aggregation of these results in specific molecular 
complexes and biological pathways has the ring of scientific truth. In schizophrenia, for 
example, genes encoding the postsynaptic components of excitatory synapses and the 
subunits of the L-type calcium channel are represented disproportionately among the 
emerging genetic findings.
Biological interpretation
For biologists, the growing torrent of results from CVAS (GWAS) creates an enormous set 
of challenges. These results have strong levels of statistical evidence, but have qualities that 
have made them challenging to exploit by traditional methods.
Modest effects
The common haplotypes implicated in common-variant association studies (Box 3) are 
genetic nudges rather than genetic shoves. For example, CVAS (GWAS) for schizophrenia 
and bipolar disorder both find associations to the same set of common SNPs in the 
CACNA1C gene, encoding a subunit of the L-type calcium channel—a molecular complex 
that is also implicated in psychiatric disease phenotypes by common polymorphisms in other 
subunits such as CACNB2 (refs. 5,24,25). The risk haplotype of CACNA1C—a haplotype is 
a set of genomically nearby alleles that segregate as a unit —is present at an allele frequency 
of 35% in populations of European ancestry. Each inherited copy increases risk by about 
15%, thus increasing a carrier's risk from the approximately 1.00% average population 
prevalence to 1.15%. Each such risk allele explains only a small fraction of variation in risk 
in the population. Moreover, in each person carrying this genetic risk factor (most of us 
carry one copy; many carry two) it acts within a genetic background that contains many 
other genetic influences (some increasing risk, some protective) of a similar magnitude.
Alleles of modest effect are often found in genes of large effect. For example, CACNA1C 
also harbors rare variants that profoundly disrupt organ development (including Mendelian 
causes of Timothy syndrome26). These large-effect variants so severely disturb the 
development and function of the brain and other organ systems that they obscure most 
psychiatric phenotypes. The effects ascertained in CVAS (GWAS) may represent milder and 
tissue-specific perturbations in the expression of the associated genes, rather than knockouts 
or, as in the case of Timothy syndrome, a toxic gain of function. CVAS (GWAS) has allowed 
such partial perturbations to be related to natural variation in phenotypes. Still, the partial 
and tissue-specific nature of these genetic perturbations makes them challenging to study by 
traditional biological methods.
Different combinations in different genomes
Common variants appear in different combinations in every human genome. Part of the 
reason for the modest explanatory power of individual common variants is likely that, in 
diverse human populations, each is only one of many genetic and environmental influences 
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on the phenotype. As functional alleles begin to be identified and studied experimentally on 
isogenic backgrounds in controlled environments, their relationship to specific molecular 
and cellular phenotypes may be clearer than it is today. An important technology for 
analyzing such variants may involve techniques for precisely editing genomes27,28 whether 
in cell lines or in animal models (further described below).
Functional alleles not yet known
A given SNP that is identified in common-variant association studies is generally a 
molecular proxy (or `tag') for a set of 5–50 common polymorphisms that co-segregate as a 
haplotype. The specific allele(s) on that haplotype that influence the phenotype are not 
initially known—and have been identified in only a few cases to date29–31. Moreover, the 
genetic architecture of the functional alleles may not be identical that of the associated 
SNPs: an association to a haplotype could also arise from lower-frequency alleles that 
segregate on that haplotype, or from combinations of multiple genetic effects at the same 
locus. Our still limited knowledge of the underlying functional allele(s) makes it challenging 
to model the genetic perturbation in cell lines or animals.
Noncoding variants and regulatory DNA
Most of the haplotypes implicated in CVAS (GWAS) do not contain protein-altering variants 
but rather reside within large introns or in sequences upstream of nearby genes, locations 
that often contain tissue-specific enhancer elements. Thus, while they can often be mapped 
to recognizable genes, the functional effects of risk-associated sequence variation on those 
genes has been challenging to establish in systematic ways. One might conclude that their 
effects arise not from `broken' proteins but from quantitative variation in expression levels or 
alterations in cell type–specific expression patterns. Cases in which the functional alleles 
have been identified support the hypothesis of tissue-specific effects on gene 
expression29–31. Noncoding variants in human genes are challenging to model in other 
organisms, as regulatory sequences appear to evolve on faster time scales and show less 
conservation than protein-coding sequences do. Though identifying functional alleles within 
noncoding sequence is a challenging problem, progress will likely be accelerated by data 
resources that annotate chromatin states in diverse cell types32. Overall, noncoding variation 
may be a way in which natural polymorphism found in populations differs from the severe 
mutations that scientists often create in model organisms, which produce phenotypes far 
outside of the organisms' normal range.
Interpreting emerging genetic results: rare variants
Although less is known today about the contribution of rare variants to polygenic 
phenotypes, there is a strong theoretical case that some of them are quite significant: alleles 
that strongly predispose to disease are likely to be kept at low frequencies by purifying 
selection. Such rare variants must be ascertained in each genome by sequencing. Sequencing 
DNA from large numbers of affected individuals makes it possible to begin to explore the 
relationship of such variants to psychiatric and other phenotypes (Box 5). Innovations in 
genome sequencing technology are starting to allow such studies to be pursued on a large 
scale.
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The basic challenge in any rare-variant association study (RVAS) is that human genomes 
contain thousands of variants that alter or terminate protein sequences, complicating the 
assignment of disease causality to any particular variant33. Natural variation in human 
populations contrasts sharply with the isogenic context in which mutations are studied in 
most model organisms. In diverse populations, the properties of gene-disabling and gene-
altering variants in a particular gene become clear only as such variants are observed in 
many individuals. For many rare, monogenic disorders with recognizable and unusual 
defining phenotypes (such as Kabuki Syndrome), such results yielded quickly to exome 
sequencing, as most patients have mutations in the same gene. For polygenic disorders, far-
larger samples have been required before individual genes even begin to stand out from the 
background of vicissitudes across the genome. Moreover, even where rare variants of large 
effect have been ascertained – the clearest example today are CNVs (Box 4) – they show 
only partial penetrance for adult-onset psychiatric phenotypes such as schizophrenia; most 
carriers have no psychiatric diagnosis, though subclinical effects on IQ and cognition may 
be more common (Box 4).
Nonetheless, rare variants, when ascertained across large numbers of individuals, can begin 
to aggregate into patterns that reveal excesses of these variants in affected or unaffected 
individuals. [Trying to combine this with the following paragraph, but my version of Word 
isn't accommodating.]The strongest influences of rare variants, including de novo mutations, 
have been documented in congenital and early-childhood-onset disorders such as intellectual 
disability (ID) and autism. In these disorders, affected individuals appear to have increased 
likelihood of a protein-disrupting mutation, and such mutations have been observed 
recurrently in specific genes (such as CHD8, SCN2A, GRIN2B and DYRK1A) at 
statistically elevated rates, often with broad phenotypic impacts including seizures and 
severe intellectual disability19–22. In highly heritable later-onset disorders, such as 
schizophrenia, affected individuals appear to carry rare mutations in exons at a rate that only 
modestly exceeds that of the general population and that is lower than in individuals with 
autism or ID18. This subtler enrichment suggests that such mutations play a smaller role in 
schizophrenia than in early-onset developmental disorders such as autism and ID. Indeed the 
mutations in schizophrenia patients have not yet shown evidence of accumulation in 
individual genes, although as a group they exhibit patterns of statistical enrichment among 
sets of functionally related brain-expressed genes34 such as those that encode postsynaptic 
components of excitatory synapses17 and those that encode RNA targets of the fragile X 
mental retardation protein (FMRP)18.
As studies based on sequencing are expanded to more patients and controls, a growing set of 
genes is likely to be implicated by allelic series of rare variants. Such findings would present 
great opportunities for biological studies by permitting measurement of functional effects 
across allelic series, exploration of their consequences for cellular phenotypes, and attempts 
to relate them to clinically significant phenotypes in patients. Protein-altering variants of 
large effect generally provide an easier starting point for biological studies than the 
regulatory variants implicated in CVAS (GWAS) do. However, RVAS are still well short of 
the sample sizes needed to implicate large numbers of specific genes in adult-onset 
psychiatric disorders. A critical challenge for biologists will be to decide when functional 
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studies are merited– in particular, to avoid premature hypotheses born of biological 
plausibility and `Just So' stories. Demonstration that similar concentrations of rare variants 
(in pathways and specific genes) are not present in cohorts of unaffected individuals will 
strengthen confidence in RVAS results. The expansion of exome and whole-genome 
sequencing studies to much larger cohorts of affected and unaffected individuals will be key 
to arriving at genetic findings that are neurobiologically actionable with reasonable levels of 
confidence.
The challenge of polygenicity for neurobiology
As described, both common and rare alleles emerging from the analysis of psychiatric 
disorders have limited penetrance, act in concert with many other alleles (genetic 
backgrounds) and contribute to multiple phenotypes (are pleiotropic). However, for practical 
reasons, the predominant modern experimental approach to functional analysis of disease-
associated genes is based on variants of high penetrance35 introduced into mice. Based on 
the emerging polygenic architecture of psychiatric disease, we would suggest that current 
approaches increasingly must be complemented by new appproaches that permit far higher 
throughput (than for example does the production of mutant mice), that are more inductive 
in nature, and that permit analysis of biological systems beyond a single hypothesis about a 
putatively causal allele. We must go beyond narrow pathophysiological hypotheses derived 
from small, disconnected islands in the research literature, to systematic ways of gathering 
information and deriving insight from neurobiological systems. Just as genome-scale 
experimental tools and data resources and unbiased (hypothesis-free) approaches to data 
collection and analysis have given new life to genetics, so they may offer new opportunities 
to molecular and cellular neurobiology. To understand how genetic perturbations affect 
specific cell populations, biologists will need a better census the of cell populations present 
in each brain region, along with experimental tools to systematically identify perturbations 
of their cellular states. This will require development not only of new experimental tools, 
such as scalable approaches to single-cell expression profiling and cellular models based on 
stem cell technologies, but also of a new generation of fundamental data resources, such as 
reference transcriptomes for each of the major cell populations in the brain. Single-cell 
proteomics is not yet possible, but it will be critical to develop methods that can determine 
which proteins in a putative pathway or network actually coexist in the same cell at the same 
time. Ultimately, validation will also require data from postmortem human brains. We do not 
argue that neurobiologists should await such data before exploring the function of disease-
associated alleles; rather we urge that such molecular resources be developed in parallel in 
order to diminish speculative risks associated with therapeutic target identification and the 
process of target validation.
Systems neurobiologists will also not lack for challenges. After all, the symptoms and 
impairments of psychiatric disorders result from abnormal functioning of neural circuits. 
Thus successful investigation of disease mechanisms is likely to require scalable assays for 
neuronal structure, function and connectivity applied to primary or reprogrammed neurons 
in vitro (human, rodent, or other species) and to multiple animal models including 
Drosophila, zebrafish, rodents and nonhuman primates.
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Studies of genetically engineered mice for translational neurobiology will remain important 
when studying neural circuits that are structurally as well as functionally conserved—
possibly along with the underlying molecular networks, as appears to be the case for basal 
ganglia circuit dysfunction in repetitive behavior36—in evolution. However, modeling 
deficits in higher brain function, such as working memory and social cognition, in rodents is 
challenging owing to differences in brain structure (cell types, circuits and regional 
architecture) between rodents and humans. Structural and functional defects in the 
dorsolateral prefrontal cortex of the brain of patients with schizophrenia are considered an 
important cause of working memory deficits37. This structure is unique to primates38, which 
makes it challenging to use rodent studies as predictors of therapeutic efficacy. It now 
appears possible to turn to other models, such as the common marmoset, a small New World 
monkey with a fast reproduction cycle, to study the neural circuits and biomarkers of 
psychiatric disorders39.
The model selected should be based not only on the feasibility of experimentation with 
current methods but also, more importantly, on the questions being asked. For research that 
attempts to translate basic biological findings into understanding of pathogenesis or 
discovery of therapeutics, it is particularly important to attend to evolutionary conservation 
with humans. What has been called `face validity'—the similarity of a physiologic finding or 
a behavior in an animal model to the human disease—is a quite treacherous guide, even if 
the behavior under study appears similar from animal model to human40. The same 
structures or behavior can arise by convergent evolution from very different underlying 
mechanisms. Unless the underlying mechanisms are conserved, it matters little whether a 
cognitive or behavioral phenotype appears very similar or identical in an animal model and a 
healthy or ill human. A drug acts on targets within molecular networks, thus influencing 
synapses and circuits and only as a result affecting cognition, emotion and behavior.
Convergence of neurobiology with human genetics
Important future progress in psychiatric research may arise at the interface of neurobiology 
and human genetics. These two fields have enormous potential synergies; yet they have 
realized few of these synergies to date, and their separate success has involved revealing 
very different kinds of relationships in biological systems. Biological inquiry is based upon 
establishing cause-and-effect relationships in well-controlled experiments. Such 
relationships have often been clearest when they involved experiments with highly penetrant 
genetic defects (such as homozygous knockouts) and other dramatic experimental 
perturbations. This work has established powerful models about how the components of 
neurons and circuits work – though with little understanding of how natural variation in 
these components could underlie common psychiatric phenotypes. Human genetic studies of 
psychiatric disorders were organized initially around an unsuccessful quest for similarly 
simple, general, high-penetrance relationships, and then around an unsuccessful assumption 
that the relevant candidate genes could be predicted from biological understanding. Most 
confirmed genetic findings today have come from starting over with unbiased genome-wide 
searches – and embracing the situation that exists when hundreds of modest, common and 
often one or a few stronger-impact (but only partially penetrant), rare genetic perturbations 
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inhabit every genome. This is creating a wealth of genetic discoveries for which no facile 
biological playbook exists.
Such a playbook will need to be written in the coming years. The synthesis of these ways of 
understanding brain function and dysfunction will offer fundamental intellectual challenges
—and, we hope, important scientific insights and medically transformative ideas.
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Box 1 Linkage studies
Linkage analysis attempts to identify genomic segments that are shared by individuals in 
a family who are affected by the same disorder. The underlying hypothesis is that shared 
DNA segments contain a sequence variant that is highly penetrant in regard to the disease 
phenotype.
Linkage studies have been most successful for diseases that have a simple, monogenic 
architecture—i.e., that segregated with a single genetic variant within a family and with 
variants (which may be different) within the same gene in other families. This allows 
evidence for a gene to accumulate across families, as was the case for the CFTR gene in 
cystic fibrosis, since a single family is generally too small to zero in on one locus.
Linkage analysis has been unsuccessful when extended to genetically complex disorders 
(such as many psychiatric disorders) that are influenced by different combinations of 
variants in the same family or by different constellations of genes in different families. In 
such cases, linkage studies fail to produce results that are statistically strong or broadly 
replicated. Today, we understand that psychiatric disorders are influenced by both rare 
and common variants in hundreds of genes; that the observation of multiple affected 
individuals in the same family does not represent the action of a shared, highly penetrant 
variant; and that such variants, when they do exist, are present in only a small percentage 
of families.
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Box 2 Candidate-gene association studies
Candidate-gene association studies are hypothesis-driven evaluations of specific variants 
in a particular gene, most often chosen on the basis of a biological hypothesis. This 
approach contrasts with unbiased genome-scale approaches represented by common- or 
rare-variant association studies. Candidate-gene association studies have been most 
successful for diseases in which the relevance of the selected gene to the biology of the 
disorder was already well established. For example, candidate-gene studies have 
identified both common and rare alleles in genes already known to influence serum lipid 
phenotypes such as levels of low-density lipoprotein and triglycerides41. For psychiatric 
disorders in which the underlying biology is not yet understood, candidate-gene studies 
involve more speculation about the relevance of the selected gene and thus have a smaller 
prior probability of detecting a true association. Across a field in which different 
laboratories are collectively testing hundreds of candidate hypotheses, P values of 0.01 or 
0.001 will very frequently be reached by chance, even if the alleles in question bear no 
true underlying relationship to the phenotype.
Moreover, publication bias has almost certainly favored the preparation, submission and 
publication of positive studies over negative studies. Thus, even the presence of multiple 
positive studies in the literature does not necessarily imply a true genetic effect on 
phenotype. In fact, many biological candidate genes that have been reported to be 
associated with psychiatric disorders show no evidence of association in today's well-
powered, unbiased genome-wide searches.
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Box 3 Common-variant association studies
Genome-wide common-variant association studies (CVAS) involve the analysis of 
millions of common sequence polymorphisms (single-nucleotide polymorphisms, SNPs) 
in a genome-wide search for alleles that are more common in affected than in unaffected 
individuals. CVAS have more often been referred to as genome-wide association studies 
(GWAS), though this term can be confusing, as rare-variant studies by sequencing (Box 
5) also represent genome-wide searches for association42. (Since the use of the term 
`CVAS' is new42, we use both acronyms here.)
Human populations expanded from a few thousand to 7 billion individuals over fewer 
than 100,000 years (5,000 generations). The sequence variation that was present in those 
small, ancestral populations 100,000 years ago is today common and found throughout 
the world; this allows such polymorphisms to be evaluated, on thousands of genetic 
backgrounds and in diverse environmental contexts, for relationship to disease. Human 
populations contain about 10 million common sequence polymorphisms, almost all of 
which trace back to these ancestral populations. Whole-genome sequencing has allowed 
these polymorphisms to be systematically catalogued, as by the 1000 Genomes Project14. 
Moreover, polymorphisms near one another on a chromosome often carry strong 
statistical relationships to one another—a phenomenon called linkage disequilibrium 
(LD)—such that, by genotyping only a few hundred thousand well-selected 
polymorphisms across the genome, one can statistically infer (`impute') the state of most 
of the others. Thus, in a CVAS (GWAS) large numbers of samples can be genotyped by 
low-cost SNP arrays (~$100/sample) designed to detect several hundred thousand 
common variants with other variants statistically imputed16. (The allelic states of 
common variants can also be ascertained with sequencing; common-variant studies may 
eventually use sequencing when its cost begins to approach that of array-based analyses, 
but for now the use of arrays supports the analysis of larger cohorts.)
Because a genome-wide search comes with a high burden of multiple hypothesis testing, 
CVAS (GWAS) demand a high level of statistical evidence for relationship to disease: a 
typical threshold is 5 × 10−8. This level is hard to reach when a variant is just one of 
many common risk factors, and thus the primary determinant of the success of CVAS 
(GWAS) has been sample size.
CVAS (GWAS) for psychiatric disorders initially appeared unsuccessful, though with 
expanded sample sizes they are now implicating large numbers of specific loci5.
A SNP that is reported in a CVAS as associated with disease is almost always a marker 
for a set of sequence polymorphisms that are nearby in the genome and that segregate 
together as a haplotype. Haplotypes are sets of sequence alleles that travel together in 
human populations on a short chromosomal segment that are seldom disrupted by 
recombination. It is really this haplotype `tagged' by the SNP that is associated with a 
disease; the haplotype is likely to contain one or more functional variants that influence a 
biological process relevant to the disease.
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Box 4 Studies of copy number variation (CNV)
The early array-based tools use to genotype common single-nucleotide polymorphisms 
(SNPs) across the genome were redesigned for the simultaneous analysis of copy number 
variation (CNV)—deletions and duplications of genomic segments30. Such efforts 
yielded surprisingly quick results; CNVs turned out to be principal early discoveries of 
array-based CVAS (GWAS) for autism and schizophrenia in early studies with sample 
size in the low thousands43,44. As such studies have expanded, more than a dozen loci 
have been found at which large (>200 kb), recurring deletions or duplications are present 
in 0.1–1% of affected individuals but are 3–30 times rarer in the general population45. 
Most such results are by now well replicated. The challenges in using CNVs for 
neurobiology are twofold: their intrinsic complexity and the frequency with which they 
contribute to diverse disease phenotypes. Because many CNVs encompass large numbers 
of genes, it has proven difficult to determine whether their damaging effects are mediated 
by a single gene or by interactions among genes within the CNV, much less what specific 
gene(s) are involved. The most penetrant central nervous system phenotype across 
recurring CNVs is intellectual disability, with a fraction of those affected also having 
attention deficit hyperactivity disorder, autism or schizophrenia. Indeed, the relationship 
of a CNV to phenotype in any individual is very likely dependent on genetic background 
as well as nongenetic factors
Analysis of CNV results to date supports polygenic models of autism and schizophrenia. 
Large (500 kb), de novo, genic CNVs found at any genomic locus are observed several 
times more frequently in patients with autism than in controls46. However, these CNVs 
are distributed across a large number of genomic sites (only a small minority arise from 
recurrent mutations at the same sites), giving rise to an estimate that at least 130–234 
regions of the human genome can mutate to substantially increase autism risk46.
Another important lesson from CNVs relates to partial penetrance. Large deletions and 
duplications (of 4 to 50 genes) are strong genetic perturbations, yet the large, recurring 
CNVs implicated in schizophrenia carry odds ratios of 3 to 30 – i.e. they may increase 
risk from a background rate of say 1%, to 3-30%. The great majority of carriers therefore 
do not have the phenotype in question, though a recent study shows that they may often 
have subclinical effects on cognition and IQ.
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Box 5 Rare-variant association studies
Rare-variant association studies (RVAS, often called `sequencing studies' or `exome 
sequencing studies') involve a search for rare sequence variants, including new (`de 
novo') mutations, via sequencing. Most rare variants occur too infrequently to allow 
association testing of individual variants; analyses of rare variants thus involve 
aggregating such variants into gene- or pathway-based sets and evaluating their aggregate 
frequency as a group.
Most rare-variant studies to date have focused on the protein-coding parts of the human 
genome (the exome)—both because potentially functional variants can be distinguished 
from neutral or synonymous variants and because the exome (which comprises only 
about 1.5% of the human genome) requires less sequencing than the whole genome, 
allowing larger numbers of patients to be sequenced in a study. As sequencing costs fall, 
exome-sequencing studies may give way to larger numbers of whole-genome sequencing 
studies.
Rare-variant studies involve one of three principal designs: case-control, trio and other 
family designs.
Case-control. Case-control studies are the mainstay of disease association in CVAS. For 
rare variants they involve sequencing, by the same methods at the same time, a large 
number of affected and unaffected individuals drawn from the same population. Data 
from the control individuals is used to calibrate how surprising the observation of any set 
of variants is—for example, whether a given gene (or a functionally related set of genes) 
harbors significantly more loss-of-function variants in affected than in unaffected 
individuals. Careful statistical calibration is important, as genomes are replete with rare 
sequence variation; on average each individual possesses thousands of protein-altering 
sequence variants, of which about 100 disrupt the function of the encoded protein33,47.
The design of case-control RVAS involves important methodological issues around 
choosing samples. First, it is important that cases and controls be well matched—that 
they be drawn from the same population and analyzed by the same methods at the same 
time—as ancestry can profoundly shape the number of variants in a genome, and 
laboratory and computational methods influence the extent to which those variants are 
ascertained. This holds true for CVAS as well. Second, as studies grow beyond initial 
explorations in individual populations, an increasingly important decision will involve 
what populations to sequence in future studies. For example, rare protective alleles of 
APP and PCSK9 were discovered due to their relative enrichment in the study 
populations46,48. Populations with unique histories such as bottlenecks may be 
particularly useful for uncovering effects of recessive variants.
Trios. Trio-based studies focus on new mutations as a way to filter out the thousands of 
protein-altering variants that are inherited by each individual. In these studies, DNA is 
collected from affected individuals and their unaffected parents. Sequencing father, 
mother and proband allows new mutations to be distinguished from the far larger number 
of inherited variants. Most genomes contain about 60 new mutations not present in either 
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parent's genome; usually about 0–2 of these new mutations will be present in the exome, 
and about half of these will affect the sequence of an encoded protein.
The analytical challenge in trio-based mutation studies is that protein-altering mutations 
arise in a substantial fraction of all individuals (regardless of phenotype); identifying the 
subset that contributes to disorders in affected individuals is therefore challenging. Trio-
based studies thus seek patterns among the mutations (in affected individuals) that appear 
nonrandom—such as a tendency of such mutations to cluster in specific genes or in 
constellations of genes with related functions or expression patterns18–22. For simple, 
monogenic diseases, this has often led to quick identification of a culpable gene. For 
genetically complex psychiatric disorders, the analytical challenge has been much more 
difficult and involves the gradual accretion of statistical evidence in individual genes or in 
large constellations of functionally related genes that are defined, for example, by co-
localization or similar functional annotation of the encoded proteins. Generally only a 
minority of ascertained mutations contribute to such patterns, so statistical power has 
been key for making such inferences. For example, CHD8 was implicated as an autism 
gene through trio-based studies, though CHD8 mutations were present in less than 1% of 
cases;[sequencing of hundreds of trios was necessary before this pattern became 
clear19,21,22. In designing trio-based studies for other complex diseases, one can try to 
increase the frequency of impactful mutations by selecting sporadic cases (affected 
individuals without affected relatives). New mutations may also be enriched among 
patients who have syndromes involving many or more severe phenotypes (such as autism, 
epilepsy and low IQ) rather than more common presentations of the disorder.
Other family-based designs. Other study designs utilize cohorts that were initially 
collected for linkage analysis (i.e., families with multiple affected individuals) and 
attempt to winnow large sequencing data sets by making the kinds of assumptions that 
linkage analysis makes—for example, that affected individuals drawn from the same 
family must share a causal variant in common with one another. The challenge in such 
analyses is that even randomly selected individuals in any family will share substantial 
fractions of their genomes in common, and this shared part of the genome will include 
both rare and common variants affecting the sequences of large numbers of genes. The 
prioritization of individual variants therefore often involves evaluation based on 
biological candidacy or independent forms of genetic evidence from other studies. An 
increasingly common design is to see the family analysis as a hypothesis-generating 
process, after which nominated genes are then sequenced and analyzed in larger, well-
powered case-control cohorts to test for formal disease association.
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Figure 1. 
Allele frequency represents a continuum in human populations, with cutoffs between 
`common' and `rare' being somewhat arbitrary. On the left we display the frequency of 
common variants (common polymorphisms) and the large range of frequencies of rare 
variants. On the right we display the methodologies used to detect these various types of 
variation depending. For rare variants, design is based not only on allele frequency but also 
on whether the variant is transmitted or de novo. Whole-genome sequencing is not depicted 
because it has not yet been broadly incorporated into published studies in psychiatric 
genetics.
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